What we do Bal Pharma Ltd develops, manufactures, and markets specialty pharmaceutical formulations and bulk drugs, focusing on branded generics across multiple therapeutic areas in India and over 30 countries. |
Founded in 1,987 |
Market share A significant player in Indian pharmaceutical formulations with a diversified product range and growing global export presence. |
Problem solved Addressing healthcare needs by providing affordable, high-quality branded generic medicines and APIs to patients and healthcare providers worldwide. |
Top clients or who we serve Pharmacies, hospitals, and healthcare providers in India and international markets; primarily B2B and B2C segments. |
Key management - |
Our journey and innovations Since 1987, expanded formulations and API manufacturing; established subsidiaries focused on R&D and healthcare services; introduced new cardiac and diabetic specialty products recently. |
Where we operate Mainly in India with exports constituting 60% of revenue to over 30 countries worldwide. |
Top products or what we offer Pharmaceutical formulations including Paracetamol, Alprazolam, Gliclazide, Rifampicin, and specialty products like Sitagliptin combinations under brand names SITABEND and SITABEND-M. |
Top brands SITABEND & SITABEND-M - diabetic care; AZIWIN & CAFIMOL - ethical division products; Meloxi & Progit-MPS - pain management; Zanovid - antibiotic range. |
Raw materials needed Active pharmaceutical ingredients (APIs), chemical intermediates, excipients, and packaging materials. |
Raw materials supplier Various domestic and international chemical and pharmaceutical suppliers. |
Recurring vs cyclical contribution Revenue is largely recurring from ongoing pharmaceutical sales with moderate cyclicality influenced by regulatory approvals and market competition. |
Our industry position Strong presence in Indian pharma formulations market with growing API manufacturing capabilities; export-focused growth strategy. |
Financial highlights FY 2024-25 revenue approximately ₹303 crore, PAT ₹7.22 crore; exports contribute 60% of revenue, showing a stable profitability trend. |
Geographical revenue split Exports form 60% of revenue; domestic Indian market contributes 40%. |
Order book - |
Whats driving growth Increasing demand for branded generics, expansion in API manufacturing, new product launches, and international market penetration. |
Our future plans Investments in bulk drug manufacturing units, expanded R&D, and strengthening specialty pharma and diabetic care offerings. |
Our green promise Committed to energy conservation and sustainability in manufacturing processes with adherence to environmental regulations. |
Our people and values Nearly 986 employees fostering innovation, compliance, safety, and social responsibility within a professional, inclusive culture. |
Key challenges ahead Competitive pharmaceutical market, regulatory compliance, raw material price volatility, and global market access risks. |
Interesting facts Bal Pharma launched Sitagliptin and its Metformin combo recently, expanding its footprint in diabetic care segment. |
Risks and strategy Focused risk management policies to mitigate operational, financial, and regulatory risks with emphasis on innovation and market diversification. |
